webcast resource

Markers in Cancer

A Joint Meeting by ASCO, EORTC and NCI

November 07, 2013 - November 09, 2013 | Square - Brussels Meeting Centre

Markers in Cancer

Next generation sequencing and high throughput screening technologies are revolutionizing our current molecular understanding of cancer. In addition, molecular tumor profiles can now be established at affordable cost within a timeframe compatible with clinical practice. It is anticipated, that in the coming decade biomarker-based patient selection will move to the forefront of effective cancer treatment for the majority of patients.

This year’s program will address the challenges we face, the opportunities which await us, and focus on the relevance and the feasibility of implementing emerging technologies in clinical practice. You will learn the ins and outs of current biomarker research including next generation biomarker discovery as well as the development and quality control necessary to turn next generation biomarkers into reliable diagnostics. Furthermore, it is likely that clinical trial design involving multiplex biomarker testing and molecular imaging will have to be adapted to provide evidence of which (combination) treatment is most effective for the heterogeneous and genetically diverse cancer patient population presenting in the clinic.


Dr Christophe LE TOURNEAU & Dr John MARTENS (Co-Chairs)